Literature DB >> 11714796

Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells.

K Reich1, A Heine, S Hugo, V Blaschke, P Middel, A Kaser, H Tilg, S Blaschke, C Gutgesell, C Neumann.   

Abstract

Preferential uptake and presentation of IgE-bound allergens by epidermal Langerhans cells (LC) via the high affinity IgE receptor, FcepsilonRI, is regarded as an important mechanism in the induction of cutaneous inflammation in atopic dermatitis. Here, we show that activation of monocyte-derived LC-like dendritic cells (LLDC) through engagement of FcepsilonRI induces the expression of IL-16, a chemoattractant factor for dendritic cells, CD4+ T cells, and eosinophils. We found that ligation of FcepsilonRI on LLDC derived from atopic dermatitis patients that express high levels of FcepsilonRI increases IL-16 mRNA expression and storage of intracellular IL-16 protein and enhances the secretion of mature IL-16 in a biphasic manner. An early release of IL-16 (peak at 4 h) is independent of protein synthesis, while a more delayed release (peak at 12 h) requires protein synthesis and occurs subsequent to the induction of IL-16 mRNA and intracellular accumulation of pro-IL-16. There was evidence that LLDC use caspase-1 to process IL-16, as inhibition of caspase-1, but not of caspase-3, partially prevented the release of IL-16 in response to ligation of FcepsilonRI. In an in vivo model of IgE-dependent LC activation, the atopy patch test, positive skin reactions were also associated with the induction of IL-16 in epidermal dendritic cells. These data indicate that IL-16 released from LC after allergen-mediated activation through FcepsilonRI may link IgE-driven and cellular inflammatory responses in diseases such as atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714796     DOI: 10.4049/jimmunol.167.11.6321

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  A canine model of cutaneous late-phase reactions: prednisolone inhibition of cellular and cytokine responses.

Authors:  Cherie M Pucheu-Haston; Dale Shuster; Thierry Olivry; Philippe Brianceau; Patrick Lockwood; Terrill McClanahan; Rene de Waal Malefyt; Jeanine D Mattson; Bruce Hammerberg
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

2.  [Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].

Authors:  J Schmitt; K Schäkel
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

Review 3.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

Review 4.  Immunoglobulin E-Mediated Autoimmunity.

Authors:  Marcus Maurer; Sabine Altrichter; Oliver Schmetzer; Jörg Scheffel; Martin K Church; Martin Metz
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

Review 5.  Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis.

Authors:  Natalija Novak; Thomas Bieber; Stefan Kraft
Journal:  Curr Allergy Asthma Rep       Date:  2004-07       Impact factor: 4.919

Review 6.  Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2003-12       Impact factor: 2.198

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.